Author:
Sadik Noha A.,Ahmed Nagwa R.,Mohamed Moataz F.,Ashoush Omar A.
Abstract
Background:
Hepatocellular Carcinoma (HCC) is one of the most common cancers associated with deaths worldwide and the presence of valid biomarkers for early diagnosis in high-risk patients can ameliorate the outcome of HCC. Vascular Endothelial Growth Factor (VEGF) has been found to play an essential role in the process of HCC growth and progression.
Objectives:
Therefore, we evaluated the serum VEGF levels in patients with HCC and liver cirrhosis and estimated its significant value for differentiating HCC patients from liver cirrhosis patients.
Material and methods:
Eighty-one subjects were enrolled in the study, 30 patients had HCC, 31 patients had liver cirrhosis and 20 were healthy control subjects. VEGF and AFP were measured using ELIZA. Abdominal ultrasound and triphasic abdominal computed tomography were performed in all subjects. Receiver Operating Characteristics curve analysis was performed for serum VEGF to determine its validity as a tumor biomarker.
Results:
The median levels of the serum VEGF were highly expressed in the HCC group (418 pg/ml) and the liver cirrhosis group (308 pg/ml) with no significant difference (P = 0.767); however both groups showed a significant increase compared to the control group (0.8 pg/ml, P <0.000). Serum VEGF showed high sensitivity (100%) and high specificity (100%) in differentiating HCC patients from controls with a cut-off value of ≥ 64.2 pg/ml, although it showed low sensitivity (29.2%) and specificity (85.7%) for differentiating HCC patients from liver cirrhosis patients.
Conclusion:
VEGF can be used as a reliable biomarker for differentiating HCC patients from healthy subjects but it can't be used as a reliable biomarker for differentiating HCC patients from high-risk patients as liver cirrhosis. The elevated serum VEGF levels in HCC and liver cirrhosis patients can elucidate the crucial role of angiogenesis in HCC and liver cirrhosis.
Publisher
Bentham Science Publishers Ltd.
Subject
Biochemistry, medical,Clinical Biochemistry,Medicine (miscellaneous)
Reference48 articles.
1. Chen JG, Zhu J, Zhang YH, Chen YS, Ding LL.
Incidence trend of liver cancer: An analysis of 40 year’s data from Qidong population-based cancer registry.
Zhong Guo Zhong Liu
2014;
23
(8)
: 621-8.
[Google Scholar].
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.
Global cancer statistics.
CA Cancer J Clin
2011;
61
(2)
: 69-90.
3. Siegel R, Naishadham D, Jemal A.
Cancer statistics, 2012.
CA Cancer J Clin
2012;
62
(1)
: 10-29.
4. Llovet JM, Burroughs A, Bruix J.
Hepatocellular carcinoma.
Lancet
2003;
362
(9399)
: 1907-17.
5. Bruix J, Sherman M.
American Association for the Study of Liver Diseases.
Management of hepatocellular carcinoma: An update.
Hepatology
2011;
53
(3)
: 1020-2.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献